Puramed will launch 3 big drugs in 1Q 2011.
If you like EDAP you will like PMBS too .Market cap of 2,8 million$ is massive undervalued . This stock is under Radar .
Get in now before the stock gets Discovered !!! Easy money at this level .
Market Cap: 2,8 M$
Cash : 5 M$ agreement http://puramedbioscience.com/PR/2010_PuraMed_PR-Jun%201%202010.pdf
Price 0,19 $
Shares Out: 14.1 M ...( 9 million shares held by insiders )
Low Float : 5 M
A MUST READ ......
Only a few shares available below 1 Dollar
Why Puramed Bioscience Inc. (PMBS.OB) Should Be On Your Radar
PuraMed Bioscience, Inc. is a pharmaceutical company focused on developing and marketing a line of new, non-prescription medicines. These products target major consumer health needs, including the treatment of headaches, insomnia, and general pain. The company aims launch its first retail products within six months, and then leverage that success to become a leader in the Over-the-Counter (OTC) medicine marketplace.
Although PuraMed Bioscience is entering into a competitive market, the company’s products promise to bring innovation to the industry, allowing for faster absorption into the blood stream, greater effectiveness, fewer side effects, and lower dosage requirements. The first three products the company plans to introduce include: LipiGesic M™ (for acute relief of migraine headaches), LipiGesic H™ (for acute relief of tension headaches) and LipiGesic PM™ (for insomnia).
PuraMed is already sufficiently funded via private funding and ready to move forward with the execution of its comprehensive business plan. Recently BrokerBank analyst Philip Wright, CFA initiated investment coverage of the company and has rated the company as a “speculative buy”. Wright praised the company for running on a lean basis by keeping salaries reasonable and office overhead costs extremely low.
The share structure of the stock is also attractive with only 14,129,246 shares of common stock outstanding as of last month. PuraMed is also a fully reporting company, meaning the company must be audited by a PCAOB registered public accounting firm and must comply with the requirements of Sarbanes-Oxley. These requirements allow for greater transparency and the ability to attract a larger investor audience, subsequently enhancing shareholder value and providing greater access to capital for further growth.
With a management team bringing more than 80 years of combined industry experience, a product line addressing major healthcare needs with many competitive advantages, and a well thought-out business plan, this company is well on its way to success in the multi-billion dollar OTC medicine market. Continue to watch this company as it strives to dramatically improve the quality of life for millions of Americans.